Ar^1 and Ar^2 are independently (un)substituted aryl or heteroaryl.

[000012] The present invention also provides a pharmaceutical formulation comprising the compound of Formula I and one or more pharmaceutically acceptable ingredient or excipient.

[0013a] In one aspect, there is provided use of a compound of Formula I below or a pharmaceutically acceptable salt thereof:



Formula I

wherein X is C-D-A-Ar^2 and L is independently N or C-R; or X is independently N or C-R and L is C-D-A-Ar^2; wherein D-A is independently selected from the group consisting of: CR^1R^2-NR', S-CR^1R^2, O-CR^1R^2, R^3R^4C-CR^5R^6, $R^7C{=}CR^8$, and C≡C; E, G, M, and Q are independently N or C-R; and J and K are independently N or C;

R is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, arylalkyl, aryl, heteroaryl, hydroxy, alkyloxy, aryloxy, heteroaryloxy, acyloxy, arylacyloxy, heteroarylacyloxy, alkylsulfonyloxy, arylsulfonyloxy, thio, alkylthio, arylthio, amino, alkylamino, dialkylamino, cycloalkylamino, heterocycloalkylamino, arylamino, heteroarylamino, acylamino, arylacylamino, heteroarylacylamino, alkylsulfonylamino, arylsulfonylamino, acyl, arylacyl, heteroarylacyl, alkylsulfinyl, arylsulfinyl, heteroarylsulfinyl, hydroxysulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aminosulfonyl, substituted aminosulfonyl, carboxy, alkoxycarbonyl, cycloalkyloxycarbonyl, aryloxycarbonyl, carbamoyl, substituted carbamoyl, halogen, cyano, isocyano and nitro;

R′ is as follows:

(a) R′ is selected from the group consisting of: hydrogen, substituted or unsubstituted alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, arylalkyl, aryl, heteroaryl, hydroxy, alkyloxy, aryloxy, heteroaryloxy, acyloxy, arylacyloxy, heteroarylacyloxy, alkylsulfonyloxy, arylsulfonyloxy, thio, alkylthio, arylthio, amino, alkylamino, dialkylamino, cycloalkylamino, heterocycloalkylamino, arylamino, heteroarylamino, acylamino, arylacylamino, heteroarylacylamino, alkylsulfonylamino, arylsulfonylamino, acyl, arylacyl, heteroarylacyl, alkylsulfinyl, arylsulfinyl, heteroarylsulfinyl, hydroxysulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aminosulfonyl, substituted aminosulfonyl, carboxy, alkoxycarbonyl, cycloalkyloxycarbonyl, aryloxycarbonyl, carbamoyl, substituted carbamoyl;

(b) R′ together with the nitrogen atom it is attached to, some carbons of Ar^2, form a substituted or unsubstituted ring, which optionally includes one or more heteroatoms in the ring;

(c) R′ together with the nitrogen atom it is attached to, the carbon atom R^1 and R^2 are attached to, R^1 or R^2, form a substituted or unsubstituted ring, which optionally includes one or more heteroatoms in the ring; or

d) R′ together with the nitrogen atom it is attached to, the carbon atom R^1 and R^2 are attached to, some carbons of the aromatic ring next to this carbon, form a substituted or unsubstituted ring, which optionally includes one or more heteroatoms in the ring;

R^1 and R^2 are as follows:

(a) independently selected from the group consisting of hydrogen, halogen, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, arylalkyl, aryl, heteroaryl, acyl, arylacyl, heteroarylacyl, alkylsulfinyl, arylsulfinyl, heteroarylsulfinyl, hydroxysulfonyl, alkylsulfonyl, arylsulfonyl,

heteroarylsulfonyl, aminosulfonyl, substituted aminosulfonyl, alkoxycarbonyl, cycloalkyloxycarbonyl, aryloxycarbonyl, carbamoyl and substituted carbamoyl;

(b) R^1 and R^2 together with the carbon atom they are attached to form a substituted or unsubstituted ring, which optionally includes one or more heteroatoms in the ring;

(c) R^1 or R^2 together with the carbon atom it is attached to, the sulfur or oxygen atom next to this carbon, some carbons of the aromatic ring next to this atom, form a substituted or unsubstituted ring, which optionally includes one or more heteroatoms in the ring;

(d) when D-A is CR^1R^2-NR, R^1 or R^2 together with the carbon atom it is attached to, some carbons of the aromatic ring next to this carbon, form a substituted or unsubstituted ring, which optionally includes one or more heteroatoms in the ring; or

(e) R^1 or R^2 together with the carbon atom it is attached to, the nitrogen atom when D-A is CR^1R^2-NR, some carbons of Ar^2, form a substituted or unsubstituted ring, which optionally includes one or more heteroatoms in the ring;

R^3, R^4, R^5, R^6 are as follows:

(a) R^3, R^4, R^5, R^6 are independently selected from the group consisting of: hydrogen, halogen, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, arylalkyl, aryl, heteroaryl, acyl, arylacyl, heteroarylacyl, alkylsulfinyl, arylsulfinyl, heteroarylsulfinyl, hydroxysulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aminosulfonyl, substituted aminosulfonyl, alkoxycarbonyl, cycloalkyloxycarbonyl, aryloxycarbonyl, carbamoyl and substituted carbamoyl;

(b) R^3 and R^4 together with the carbon atom they are attached to form a substituted or unsubstituted ring, which optionally includes one or more heteroatoms in the ring;

(c) R^3 or R^4 together with the carbon atom it is attached to, R^5 or R^6 together with the carbon atom it is attached to, form a substituted or unsubstituted ring, which optionally includes one or more heteroatoms in the ring;

(d) R^3 or R^4 together with the carbon atom it is attached to, the carbon atom R^5 or R^6 is attached to, some carbons of Ar^2, form a substituted or unsubstituted ring, which optionally includes one or more heteroatoms in the ring;

(e) R^3 or R^4 together with the carbon atom it is attached to, some carbons of the aromatic ring next to this carbon, form a substituted or unsubstituted ring, which optionally includes one or more heteroatoms in the ring;

(f) R^5 and R^6 together with the carbon atom they are attached to form a substituted or unsubstituted ring, which optionally includes one or more heteroatoms in the ring;

(g) R^5 or R^6 together with the carbon atom it is attached to, some carbons of Ar^2, form a substituted or unsubstituted ring, which optionally includes one or more heteroatoms in the ring; or

(h) R^5 or R^6 together with the carbon atom it is attached to, the carbon atom R^3 or R^4 is attached to, some carbons of the aromatic ring next to this carbon, form a substituted or unsubstituted ring, which optionally includes one or more heteroatoms in the ring;

R^7 and R^8 are as follows:

(a) R^7 and R^8 are independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, arylalkyl, aryl, heteroaryl, hydroxy, alkyloxy, aryloxy, heteroaryloxy, acyloxy, arylacyloxy, heteroarylacyloxy, alkylsulfonyloxy, arylsulfonyloxy, thio, alkylthio, arylthio, amino, alkylamino, dialkylamino, cycloalkylamino, heterocycloalkylamino, arylamino, heteroarylamino, acylamino, arylacylamino, heteroarylacylamino, alkylsulfonylamino, arylsulfonylamino, acyl, arylacyl, heteroarylacyl, alkylsulfinyl, arylsulfinyl, heteroarylsulfinyl, hydroxysulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aminosulfonyl, substituted aminosulfonyl, carboxy, alkoxycarbonyl, cycloalkyloxycarbonyl, aryloxycarbonyl, carbamoyl, substituted carbamoyl, halogen, cyano, isocyano and nitro;

(b) R^7 and R^8 together with the carbon atoms they are attached to form a substituted or unsubstituted ring, which optionally includes one or more heteroatoms in the ring;

(c) R^7 together with the carbon atom it is attached to, some carbons of the aromatic ring next to this carbon, form a substituted or unsubstituted ring, which optionally includes one or more heteroatoms in the ring;

(d) R^7 together with the carbon atom it is attached to, the carbon atom R^8 is attached to, some carbons of Ar^2, form a substituted or unsubstituted ring, which optionally includes one or more heteroatoms in the ring;

(e) R^8 together with the carbon atom it is attached to, some carbons of Ar^2, form a substituted or unsubstituted ring, which optionally includes one or more heteroatoms in the ring; or

(f) R^8 together with the carbon atom it is attached to, the carbon atom R^7 is attached to, some carbons of the aromatic ring next to this carbon, form a substituted or unsubstituted ring, which optionally includes one or more heteroatoms in the ring; and

Ar^1 and Ar^2 are independently (un)substituted aryl or heteroaryl in the manufacture of a medicament for the treatment or prophylaxis of a viral infection or disease associated therewith.

[0013b] In another aspect, there is provided use of a compound of Formula II or a pharmaceutically acceptable salt thereof:



Formula II

wherein, E is independently N, N^{+}-O^{-}, or C-R; G, L, M, and Q are independently N or C-R; and J and K are independently N or C with the proviso that when n=0, E and J cannot both be N;

R is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, arylalkyl, aryl, heteroaryl, hydroxy, alkyloxy, aryloxy, heteroaryloxy, acyloxy, arylacyloxy, heteroarylacyloxy, alkylsulfonyloxy, arylsulfonyloxy, thio, alkylthio, arylthio, amino, alkylamino, dialkylamino, cycloalkylamino, heterocycloalkylamino, arylamino, heteroarylamino, acylamino, arylacylamino, heteroarylacylamino, alkylsulfonylamino, arylsulfonylamino, acyl, arylacyl, heteroarylacyl, alkylsulfinyl, arylsulfinyl, heteroarylsulfinyl, hydroxysulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aminosulfonyl, substituted aminosulfonyl, carboxy, alkoxycarbonyl, cycloalkyloxycarbonyl, aryloxycarbonyl, carbamoyl, substituted carbamoyl, halogen, cyano, isocyano and nitro;

R' is as follows:

(a) R' is independently selected from the group consisting of: hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, arylalkyl, aryl, heteroaryl, acyl, arylacyl, heteroarylacyl, alkylsulfinyl, arylsulfinyl, heteroarylsulfinyl, hydroxysulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl,

aminosulfonyl, substituted aminosulfonyl, alkoxycarbonyl, cycloalkyloxycarbonyl, aryloxycarbonyl, carbamoyl and substituted carbamoyl;

(b) R' together with the nitrogen atom it is attached to, the carbon atom R^1 and R^2 are attached to, R^1 or R^2, form a substituted or unsubstituted ring, which optionally includes one or more heteroatoms in the ring;

(c) R' together with the nitrogen atom it is attached to, the carbon atom R^1 and R^2 are attached to, some carbons of Ar^2, form a substituted or unsubstituted ring, which optionally includes one or more heteroatoms in the ring; or

(d) R' together with the nitrogen atom it is attached to, some carbons of the aromatic ring next to this nitrogen, form a substituted or unsubstituted ring, which optionally includes one or more heteroatoms in the ring;

R^1 and R^2 are as follows:

(a) R^1 and R^2 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, arylalkyl, aryl, heteroaryl, acyl, arylacyl, heteroarylacyl, alkylsulfinyl, arylsulfinyl, heteroarylsulfinyl, hydroxysulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aminosulfonyl, substituted aminosulfonyl, alkoxycarbonyl, cycloalkyloxycarbonyl, aryloxycarbonyl, carbamoyl and substituted carbamoyl;

(b) R^1 and R^2 together with the carbon atom they are attached to form a substituted or unsubstituted ring, which optionally include one or more heteroatoms in the ring;

(c) R^1 or R^2 together with the carbon atom it is attached to, the nitrogen next to this carbon, and some carbons of the aromatic ring next to this nitrogen, form a substituted or unsubstituted ring, which optionally include one or more heteroatoms in the ring; or

(d) R^1 or R^2 together with the carbon atom it is attached to, some carbons of Ar^2, form a substituted or

unsubstituted ring, which optionally includes one or more heteroatoms in the ring;

n is an integer from 0-4; and

Ar^1 and Ar^2 are independently (un)substituted aryl or heteroaryl, in the manufacture of a medicament for the treatment or prophylaxis of a viral infection or a disease associated therewith.

[0013c] The present invention further provides a method for the treatment or prophylaxis of a viral infection or disease associated therewith, comprising administering in a therapeutically effective amount to a mammal in need thereof, a compound of Formula I or a pharmaceutically acceptable salt thereof.

[0014] The present invention also provides a compound having the following general Formula II or a pharmaceutically acceptable salt thereof:



Formula II

wherein, E is independently N, N^+-O^-, or C-R; G, L, M, and Q are independently N or C-R; and J and K are independently N or C with the proviso that when n=0, E and J cannot both be N;

R is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, arylalkyl, aryl,

13. The composition of claim 9, wherein D-A is $R^7C=CR^8$ and each of R^7 and R^8 are H and the double bond in $R^7C=CR^8$ has a cis configuration.

14. The composition of claim 9, wherein D-A is $O-CR^1R^2$ and each of R^1 and R^2 are H.

15. The composition of claim 9, wherein the compound of Formula I is selected from the group consisting of: 5-[(Z)-2-(4-tert-butylphenyl)vinyl]-1-(4-isopropoxyphenyl)-benzimidazole; 1-(4-ethoxyphenyl)-5-[(4-ethylphenyl)-methoxy]benzimidazole; and 2-[4-[(Z)-2-[1-(4-isopropoxyphenyl)benzimidazol-5-yl]vinyl]phenyl]-propan-2-ol.

16. The composition of claim 9, wherein the compound of Formula I has the following Formula Ia:



Formula Ia

wherein E, G, J, L, M, Q, K, R^7, R^8, Ar^1 and Ar^2 are as defined in Formula I.

17. ~~A method for the treatment or prophylaxis of a viral infection or disease associated therewith, comprising administering in a therapeutically effective amount to a~~

~~mammal in need thereof,~~ Use of a compound of Formula I below or a pharmaceutically acceptable salt thereof:



Formula I

wherein X is C-D-A-Ar^2 and L is independently N or C-R; or X is independently N or C-R and L is C-D-A-Ar^2; wherein D-A is independently selected from the group consisting of: CR^1R^2-NR', S-CR^1R^2, O-CR^1R^2, R^3R^4C-CR^5R^6, R^7C=CR^8, and C≡C; E, G, M, and Q are independently N or C-R; and J and K are independently N or C;

R is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, arylalkyl, aryl, heteroaryl, hydroxy, alkyloxy, aryloxy, heteroaryloxy, acyloxy, arylacyloxy, heteroarylacyloxy, alkylsulfonyloxy, arylsulfonyloxy, thio, alkylthio, arylthio, amino, alkylamino, dialkylamino, cycloalkylamino, heterocycloalkylamino, arylamino, heteroarylamino, acylamino, arylacylamino, heteroarylacylamino, alkylsulfonylamino, arylsulfonylamino, acyl, arylacyl, heteroarylacyl, alkylsulfinyl, arylsulfinyl, heteroarylsulfinyl, hydroxysulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aminosulfonyl, substituted aminosulfonyl, carboxy, alkoxycarbonyl, cycloalkyloxycarbonyl, aryloxycarbonyl, carbamoyl, substituted carbamoyl, halogen, cyano, isocyano and nitro;

form a substituted or unsubstituted ring, which optionally includes one or more heteroatoms in the ring;

(e) R^8 together with the carbon atom it is attached to, some carbons of Ar^2, form a substituted or unsubstituted ring, which optionally includes one or more heteroatoms in the ring; or

(f) R^8 together with the carbon atom it is attached to, the carbon atom R^7 is attached to, some carbons of the aromatic ring next to this carbon, form a substituted or unsubstituted ring, which optionally includes one or more heteroatoms in the ring; and

Ar^1 and Ar^2 are independently (un)substituted aryl or heteroaryl, in the manufacture of a medicament for the treatment or prophlaxis of a viral infection or disease associated therewith.

18. The ~~method~~ use of claim 17, wherein each of E and J is N.

19. The ~~method~~ use of claim 17, wherein each of G, M, Q and L is C-R.

20. The ~~method~~ use of claim 17, wherein K is C.

21. The ~~method~~ use of claim 17, wherein D-A is $R^7C=CR^8$ and each of R^7 and R^8 are H and the double bond in $R^7C=CR^8$ has a cis configuration.

22. The ~~method~~ use of claim 17, wherein D-A is $O-CR^1R^2$ and each of R^1 and R^2 are H.

23. The ~~method~~ use of claim 17, wherein said compound of Formula I is selected from the group consisting of: 5-[(Z)-2-(4-tert-butylphenyl)vinyl]-1-(4-isopropoxyphenyl)-benzimidazole; 1-(4-ethoxyphenyl)-5-[(4-ethylphenyl)-methoxy]benzimidazole; and 2-[4-[(Z)-2-[1-(4-isopropoxyphenyl)benzimidazol-5-yl]vinyl]phenyl]-propan-2-ol.

24. The ~~method~~ use of claim 17, wherein said compound of Formula I has the following Formula Ia:



Formula Ia

wherein E, G, J, L, M, Q, K, R^7, R^8, Ar^1 and Ar^2 are as defined in Formula I.

25. The ~~method~~ use of claim 17, wherein the mammal is a human.

26. The ~~method~~ use of claim 17, wherein the viral infection is an Arenavirus infection.

27. The ~~method~~ use of claim 26, wherein the Arenavirus is selected from the group consisting of Lassa, Junín, Machupo, Guanarito, Sabia, Whitewater Arroyo, Chapare, LCMV, LCMV-like viruses.

28. The ~~method~~ use of claim 27, wherein said LCMV-like viruses are selected from the group consisting of Dandenong, Tacaribe, and Pichinde.

29. The ~~method~~ use of claim 17, which further comprises co-administration of at least one agent selected from the group consisting of antiviral agent, vaccine, and interferon.

30. A compound having the following general Formula II or a pharmaceutically acceptable salt thereof:



Formula II

wherein, E is independently N, N^{+}-O^{-}, or C-R; G, L, M, and Q are independently N or C-R; and J and K are independently N or C with the proviso that when n=0, E and J cannot both be N;

R is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, arylalkyl, aryl, heteroaryl, hydroxy, alkyloxy, aryloxy, heteroaryloxy, acyloxy, arylacyloxy, heteroarylacyloxy, alkylsulfonyloxy, arylsulfonyloxy, thio, alkylthio, arylthio, amino, alkylamino, dialkylamino, cycloalkylamino, heterocycloalkylamino, arylamino, heteroarylamino, acylamino, arylacylamino, heteroarylacylamino, alkylsulfonylamino, arylsulfonylamino, acyl, arylacyl, heteroarylacyl, alkylsulfinyl, arylsulfinyl, heteroarylsulfinyl, hydroxysulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aminosulfonyl, substituted aminosulfonyl, carboxy, alkoxycarbonyl, cycloalkyloxycarbonyl,

39. The composition of claim 35, wherein said compound of Formula II is selected from the group consisting of: 3-[(4-ethoxyphenyl)methyl]-N-[(4-ethylphenyl)-methyl]imidazo-[4,5-b]pyridin-6-amine; 1-(4-ethoxyphenyl)-N-[(4-ethylphenyl)-methyl]indol-5-amine; 3-(4-ethoxyphenyl)-N-[(4-ethylphenyl)-methyl]-1H-indol-6-amine; 3-(4-ethoxyphenyl)-N-[(4-ethylphenyl)-methyl]imidazo[1,2-a]pyridin-7-amine; 1-(4-ethoxyphenyl)-N-[(4-ethylphenyl)-methyl]pyrrolo[2,3-b]pyridin-5-amine; and 1-(4-ethoxyphenyl)-N-[(4-ethylphenyl)-methyl]-3-oxido-benzimidazol-3-ium-5-amine.

40. ~~A method for the treatment or prophylaxis of a viral infection or disease associated therewith, comprising administering in a therapeutically effective amount to a mammal in need thereof,~~ Use of a compound of Formula II or a pharmaceutically acceptable salt thereof:



Formula II

wherein, E is independently N, N^+-O^-, or C-R; G, L, M, and Q are independently N or C-R; and J and K are independently N or C with the proviso that when n=0, E and J cannot both be N;

R is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, arylalkyl, aryl,

R^1 and R^2 are as follows:

(a) R^1 and R^2 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, arylalkyl, aryl, heteroaryl, acyl, arylacyl, heteroarylacyl, alkylsulfinyl, arylsulfinyl, heteroarylsulfinyl, hydroxysulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aminosulfonyl, substituted aminosulfonyl, alkoxycarbonyl, cycloalkyloxycarbonyl, aryloxycarbonyl, carbamoyl and substituted carbamoyl;

(b) R^1 and R^2 together with the carbon atom they are attached to form a substituted or unsubstituted ring, which optionally include one or more heteroatoms in the ring;

(c) R^1 or R^2 together with the carbon atom it is attached to, the nitrogen next to this carbon, and some carbons of the aromatic ring next to this nitrogen, form a substituted or unsubstituted ring, which optionally include one or more heteroatoms in the ring; or

(d) R^1 or R^2 together with the carbon atom it is attached to, some carbons of Ar^2, form a substituted or unsubstituted ring, which optionally includes one or more heteroatoms in the ring;

n is an integer from 0-4; and

Ar^1 and Ar^2 are independently (un)substituted aryl or heteroaryl, in the manufacture of a medicament for the treatment or prophylaxis of a viral infection or a disease associated therewith.

41. The ~~method~~ use of claim 40, wherein each of E and K is N.

42. The ~~method~~ use of claim 40, wherein each of G, L, M and Q is C-R and R is hydrogen.

43. The ~~method~~ use of claim 40, wherein J is C.

44. The ~~method~~ use of claim 40, wherein said compound of Formula II is selected from the group consisting of: 3-[(4-ethoxyphenyl)methyl]-N-[(4-ethylphenyl)-methyl]imidazo-[4,5-b]pyridin-6-amine; 1-(4-ethoxyphenyl)-N-[(4-ethylphenyl)-methyl]indol-5-amine; 3-(4-ethoxyphenyl)-N-[(4-ethylphenyl)-methyl]-1H-indol-6-amine; 3-(4-ethoxyphenyl)-N-[(4-ethylphenyl)-methyl]imidazo[1,2-a]pyridin-7-amine; 1-(4-ethoxyphenyl)-N-[(4-ethylphenyl)-methyl]pyrrolo[2,3-b]pyridin-5-amine; and 1-(4-ethoxyphenyl)-N-[(4-ethylphenyl)-methyl]-3-oxido-benzimidazol-3-ium-5-amine.

45. The ~~method~~ use of claim 40, wherein the mammal is a human.

46. The ~~method~~ use of claim 40, wherein the viral infection is an Arenavirus infection.

47. The ~~method~~ use of claim 46, wherein the Arenavirus is selected from the group consisting of Lassa, Junín, Machupo, Guanarito, Sabia, Whitewater Arroyo, Chapare, LCMV, LCMV-like viruses.

48. The ~~method~~ use of claim 47, wherein said LCMV-like viruses are selected from the group consisting of Dandenong, Tacaribe, and Pichinde.

49. The ~~method~~ use of claim 40, which further comprises co-administration of at least one agent selected from the group consisting of antiviral agent, vaccine, and interferon.